Loading...
Please wait, while we are loading the content...
Similar Documents
Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin
| Content Provider | Scilit |
|---|---|
| Author | Rustgi, V. K. Esposito, S. Hamzeh, F. M. Shiffman, M. L. |
| Copyright Year | 2007 |
| Description | Journal: Alimentary Pharmacology & Therapeutics Peginterferon alfa-2a/ribavirin treatment resulted in fewer incidences of depression and flu-like symptoms than that of standard interferon/ribavirin, whereas peginterferon alfa-2b/ribavirin and standard interferon/ribavirin treatment resulted in similar incidences of these adverse events (AEs). To assess the efficacy and safety of peginterferon alfa-2a/ribavirin in genotype 1-infected patients treated for up to 12 weeks with peginterferon alfa-2b/ribavirin but not achieving early virologic response (EVR) (non-EVR) or nontolerant (NT) because of depression, fatigue, flu-like symptoms, or injection-site reactions. Nontolerants were treated for an additional 36 weeks and non-EVRs for an additional 60 weeks with peginterferon alfa-2a (180 microg/week)/ribavirin (1000/1200 mg/day). Patients with detectable HCV RNA after 12 weeks were discontinued. Of 25 NTs, 23 (92%) were HCV-RNA negative after 12 weeks on peginterferon alfa-2a/ribavirin and 14 (56%) achieved sustained virologic response. Of 32 non-EVRs to peginterferon alfa-2b/ribavirin, four (13%) achieved EVR with peginterferon alfa-2a/ribavirin and one (3%) achieved sustained virologic response. Four non-EVRs and 0 NTs were withdrawn for AEs; 26 (81%) and 24 (96%), respectively, completed peginterferon alfa-2a/ribavirin treatment or were withdrawn for insufficient response at week 12. In NTs, depression, fatigue, flu-like symptoms, and injection-site reactions declined during treatment. Most patients who did not tolerate peginterferon alfa-2b/ribavirin because of AEs, and who completed the full 36-week course of peginterferon alfa-2a/ribavirin treatment, achieved sustained virologic response. |
| Related Links | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2007.03587.x/pdf |
| Ending Page | 440 |
| Page Count | 8 |
| Starting Page | 433 |
| e-ISSN | 13652036 |
| DOI | 10.1111/j.1365-2036.2007.03587.x |
| Journal | Alimentary Pharmacology & Therapeutics |
| Issue Number | 5 |
| Volume Number | 27 |
| Language | English |
| Publisher | Wiley-Blackwell |
| Publisher Date | 2007-12-10 |
| Access Restriction | Open |
| Subject Keyword | Journal: Alimentary Pharmacology & Therapeutics Gastroenterology and Hepatology Hepatitis C Virus Like Symptoms Alfa 2a/ribavirin Peginterferon Alfa 2b/ribavirin |
| Content Type | Text |
| Resource Type | Article |
